Cilnidipine is a dihydropyridine calcium channel blocker with dual L- and N-type calcium channel blocking activity, offering both vasodilation and sympatholytic effects that reduce reflex tachycardia, used for hypertension primarily in Asian markets. Simson Pharma's Cilnidipine reference standard and impurities support stability-indicating method development for this dual-channel antihypertensive.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Cilnidipine Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.